EXPERIENCE WITH OUTPATIENT INTRAVENOUS TEICOPLANIN THERAPY FOR CHRONIC OSTEOMYELITIS

被引：48

作者：

GRANINGER, W ^{[1
]}

WENISCH, C ^{[1
]}

WIESINGER, E ^{[1
]}

MENSCHIK, M ^{[1
]}

KARIMI, J ^{[1
]}

PRESTERL, E ^{[1
]}

机构：

[1] UNIV HOSP VIENNA,DEPT ORTHOPAED,A-1090 VIENNA,AUSTRIA

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 1995年 / 14卷 / 07期

关键词：

D O I：

10.1007/BF01690746

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Thirty-seven patients with acute exacerbations of chronic osteomyelitis caused by methicillin-susceptible Staphylococcus aureus (n = 13), methicillin-resistant Staphylococcus aureus (n = 12), methicillin-susceptible coagulase-negative staphylococci (n = 9), methicillin-resistant coagulase-negative staphylococci (n = 1) and enterococci (n = 2) were treated intravenously with teicoplanin. After a loading dose of 7 to 16 mg/kg (median 11 mg/kg) for 4 to 7 days, patients received 9 to 25 mg/kg (median 14 mg/kg) on Mondays, Wednesdays and Fridays in an outpatient setting to reach trough serum levels between 5 mg/l and 15 mg/l. The duration of treatment ranged from 28 to 150 days (median 60 days). Cure was obtained in 14 (38 %) and improvement in 17 (46 %) cases, and failure was observed in 6 (16 %) patients. Adverse effects occurred in 6 patients, and caused discontinuation of treatment in 3 patients. The financial savings exceeded US$60,000 per patient compared with the high hospitalization costs of inpatient treatment.

引用

页码：643 / 647

页数：5

共 24 条

[1]

Waldvogel F.A., Osteomyelitis, Infectious diseases, pp. 1125-1129, (1992)

[2]

Waldvogel F.A., Vasey A., Osteomyelitis: the past decade, New England Journal of Medicine, 303, pp. 360-370, (1980)

[3]

McCue J.D., Outpatient i.v. antibiotic therapy: practical and ethical considerations, Hospital Practice, 23, pp. 208-212, (1988)

[4]

Brown R.B., Selection and training of patients for outpatient intravenous therapy, Reviews of Infectious Diseases, 13, pp. 5147-5151, (1991)

[5]

Poretz D.M., The infusion center: a model for outpatient parenteral antibiotic therapy, Reviews of Infectious Diseases, 13, pp. 5142-5146, (1991)

[6]

Wagner D.K., Collier B.D., Rytel M.W., Long-term intravenous therapy in chronic osteomyelitis, Archives of Internal Medicine, 145, pp. 1973-1978, (1985)

[7]

Eisenberg J.M., Kitz D.S., Savings from outpatient therapy for osteomyelitis, Journal of the American Medical Association, 255, pp. 1584-1588, (1986)

[8]

Goldenberg R.I., Poretz D.M., Eran L.S., Rising J., Sparks S.B., Intravenous antibiotic therapy in ambulatory paediatric patients, Paediatric Infectious Diseases Journal, 3, pp. 514-517, (1984)

[9]

Pallanza R., Berti M., Goldstein B.P., Mapelli E., Randisi E., Scotti R., Arioli V., Teichomycin: in vitro and in vivo evaluation and comparison with other antibiotics, Journal of Antimicrobial Chemotherapy, 11, pp. 419-425, (1983)

[10]

Cynamon M.H., Cranabo P.A., Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci, Antimicrobial Agents and Chemotherapy, 21, pp. 504-505, (1982)

← 1 2 3 →